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Original ArticleKlf6 protects b-cells against insulin resistance-
induced dedifferentiationChristopher Dumayne 1, David Tarussio 1, Ana Rodriguez Sanchez-Archidona 1,2, Alexandre Picard 1,
Davide Basco 1, Xavier Pascal Berney 1, Mark Ibberson 2, Bernard Thorens 1,*ABSTRACT
Objectives: In the pathogenesis of type 2 diabetes, development of insulin resistance triggers an increase in pancreatic b-cell insulin secretion
capacity and b-cell number. Failure of this compensatory mechanism is caused by a dedifferentiation of b-cells, which leads to insufficient insulin
secretion and diabetic hyperglycemia. The b-cell factors that normally protect against dedifferentiation remain poorly defined. Here, through a
systems biology approach, we identify the transcription factor Klf6 as a regulator of b-cell adaptation to metabolic stress.
Methods: We used a b-cell specific Klf6 knockout mouse model to investigate whether Klf6 may be a potential regulator of b-cell adaptation to a
metabolic stress.
Results: We show that inactivation of Klf6 in b-cells blunts their proliferation induced by the insulin resistance of pregnancy, high-fat high-
sucrose feeding, and insulin receptor antagonism. Transcriptomic analysis showed that Klf6 controls the expression of b-cell proliferation genes
and, in the presence of insulin resistance, it prevents the down-expression of genes controlling mature b-cell identity and the induction of
disallowed genes that impair insulin secretion. Its expression also limits the transdifferentiation of b-cells into a-cells.
Conclusion: Our study identifies a new transcription factor that protects b-cells against dedifferentiation, and which may be targeted to prevent
diabetes development.
 2020 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Pancreatic b-cells play a central role in glucose homeostasis by
secreting insulin in response to increases in glycemia to stimulate
glucose utilization by liver, fat, and muscle and to inhibit hepatic
glucose production. In various physiological states, such as pregnancy,
obesity, or aging, insulin target tissues become partially resistant to the
action of this hormone and preserving euglycemia necessitates a
compensatory increase in b-cell mass and insulin secretion capacity
[1e3]. This functional adaptation is, however, limited and further
worsening of insulin resistance may cause b-cell functional failure and
reduced cellular mass, leading to development of diabetic
hyperglycemia.
The mechanisms of b-cell adaptation to, or failure in insulin resistant
states are not fully understood. Analysis of the pancreas of brain-dead
organ donors showed that b-cell mass was increased in obesity but
reduced in type 2 diabetes of long duration [4]. At the time of diabetes
diagnosis, however, b-cell mass was found to be normal [5], implying
that a defect in b-cell secretion capacity precedes loss of mass. The1Center for Integrative Genomics, University of Lausanne, 1015 Lausanne, Switzerland
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to be associated with, and probably caused by their dedifferentiation
[6,7]. This process is characterized by the down-expression of genes
controlling glucose-stimulated insulin secretion (GSIS) (Slc2a2, Gck,
Kir6.2, Vddac), genes encoding mature b-cell transcription factors
(Pdx1, Nkx6.1, Pax6, Foxo1), and the expression of normally dis-
allowed genes, such as Hk1, LdhA, and Slc16a2, which modify glucose
metabolism and consequently further impair GSIS [6,7]. How b-cell
dedifferentiation is triggered is not fully understood. Earlier experi-
ments have shown that transplanting control islets into diabetic mice
led to a rapid loss of Glut2 expression and of GSIS, whereas the
transplantation of islets from diabetic animals into control mice led to
the restoration of both parameters [8,9]. Thus, disturbances in the
metabolic milieu of (pre)-diabetic mice may induce b-cell dedifferen-
tiation and failure. Hyperglycemia, elevated plasma glucocorticoids,
and free fatty acids [3,6,10e12] may contribute to induce these
deregulations.
Another aspect of the development of b-cell dysfunctions in the
presence of insulin resistance is their dependence on the genetic2Vital-IT, Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland
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Original Articlearchitecture of each individual. It is indeed known that only a fraction of
obese, insulin-resistant individuals progress to type 2 diabetes [13].
Similarly, mice with different genetic backgrounds display very het-
erogeneous deregulations of insulin secretion or insulin action when
fed a high-fat, high-sucrose (HFHS) diet. To identify genes controlling
b-cell functional adaptation, we recently used this mouse genetic di-
versity to perform a systems biology investigation of pancreatic islet
adaptation to a metabolic stress. We characterized the physiological
adaptation of mice from different inbred strains fed an HFHS diet for
different periods of time and performed parallel islet transcriptomic
analysis [14]. Weighted gene co-expression network analysis (WGCNA)
[15] yielded islet gene modules that correlated with the measured
phenotypes. Detailed analysis of one such module led to the identifi-
cation of Elovl2, an enzyme that generates docosahexaenoic acid, an
important regulator of GSIS which also confers protection against
glucotoxicity-induced apoptosis [14,16].
Here, following a similar approach, we identified and characterized the
role of Krüppel-like factor 6 (Klf6), a zinc finger transcription factor
[17], in b-cell adaptation to insulin resistance. The study of b-cell-
specific Klf6 knockout mice showed that this transcription factor is
required for b-cell proliferation during pregnancy, in response to high-
fat diet feeding, and following pharmacological induction of insulin
resistance. Furthermore, we show that Klf6 protects b-cells against
insulin resistance-induced dedifferentiation and transdifferentiation
into a-cells.
2. MATERIALS AND METHODS
2.1. Reagents
Mouse insulin and glucagon enzyme-linked immunosorbent assays
(ELISAs) were purchased from Mercodia (Uppsala, Sweden) and
radioimmunoassay (RIA) kits for insulin and glucagon were from Merck
Millipore (MA, USA). Exendin-4 was purchased from Bachem
(Bubendorf, Switzerland), and S961 and Exendin-4 Cy3 were kind gifts
from Dr. Lauge Schäffer and Dr. Jacob Hecksher-Sørensen (Novo
Nordisk, Copenhagen, Denmark), respectively.
2.2. Antibodies
Rabbit anti-Ki67 was from Abcam (ab15580). Guinea pig antibodies to
insulin and glucagon were purchased from Dako (AO564) and Linco
(4031-01 F), respectively. Rabbit anti-Glut2 has been previously
described [18]. Secondary antibodies were goat anti-rabbit immuno-
globulin (IgG) antibodies coupled to Alexa-Fluor 568 (Invitrogen;
A11036), Alexa-Fluor 488-labeled goat anti-guinea pig immunoglob-
ulin antibodies (Invitrogen; A11073) and Alexa-Fluor 488-labeled anti-
rabbit IgG antibodies (Invitrogen; A11008).
2.3. Mouse maintenance and diet
Male and female mice were housed in groups of 2e5 per cage on a
12-hr light/dark cycle with unlimited access to a standard rodent chow
diet (Diet 3436, Provimi Kliba AG, Kaiseraugst, Switzerland) or an HFHS
diet (Purified Diet 235HF, Safe Diets, Augy, France). Experiments were
performed on 10- to 32-week-old mice with the respective age- and
sex-matched control littermates. The mouse experiments were
approved by the Veterinary Office of Canton de Vaud, Switzerland.
2.4. Generation of b-cell-specific Klf6 knockout mice
Ins1Cre/þ mice [19] were crossed with Klf6flox/flox mice [20] to generate
Klf6flox/flox;Ins1Cre/þ mice (bKlf6KO) and Klf6flox/flox;Ins1þ/þmice l (Ctrl).
Genomic DNA (gDNA) was extracted with the Quick gDNA MiniPrep
kit according to manufacturer’s instructions (LucernaChem AG, Luzern,2 MOLECULAR METABOLISM 35 (2020) 100958  2020 The Authors. Published by Elsevier GmbH. TSwitzerland), and genotyping was performed by PCR analysis using the
following primers (see Figure 2) P1:50-TGGAGGAATATTGGCAACAG-3’;
P2:50-AAGCATACCGGTGCCAAG-3’; P3:50-GTCTTCCTGGCTGTCAAATT-
3’; P4:50-TGCCTCTTCATGTGCAGG-3’. Cell lineage tracing experiments
were performed using Rosa26tdtomato mice bred with Ins1Cre/þand
with Klf6flox/flox:Ins1Cre/þ to generate Klf6þ/þ;Rosa26tdtomato; Ins1Cre/þ
and Klf6flox/flox;Rosa26tdtomato; Ins1Cre/þ.
2.5. Quantitative real-time PCR and gene expression analysis
Total RNA from islets was extracted using the RNeasy Plus micro kit
(Qiagen, Hombrechtikon, Switzerland). cDNA was synthesized by
reversed transcription of 1 mg of total RNA using random primers
(Promega) and M-MLV reverse transcriptase (Promega) according to
the manufacturer’s instructions. Gene expression was measured in a
final volume of 10 ml by quantitative real-time PCR using 5 ml of Power
SYBR Green Master Mix (Applied Biosystems, Zug, Switzerland) and
2 ml of cDNA in a 7500 Fast Light Cycler System (Applied Biosystems,
Zug, Switzerland). Results were normalized to the housekeeping gene
mouse glyceraldehyde 3-phosphate dehydrogenase (GAPDH) levels.
Primers were obtained from Microsynth (Balgach, Switzerland). Specific
mouse primers for each sequence are listed in Supplementary Table 5.
2.6. Glucose tolerance test and in vivo insulin secretion
For glucose tolerance tests, mice were fasted overnight and placed in
individual cages. Blood glucose was measured from the tail vein using
a Breeze2 glucometer (Bayer, Zürich, Switzerland) before and at the
indicated times following an intraperitoneal (i.p.) injection of glucose
(2 g/kg). The same protocol was applied for in vivo insulin secretion, in
which blood sampling from the tail vein was used for plasma insulin
level measurements by ELISA.
2.7. Pancreatic insulin and glucagon content
Excised pancreata were rapidly weighed and sonicated in ethanol-acid
(75% EtOH; 0.55% HCl). After overnight storage at 4 C, samples were
centrifuged at 4 C for 5 min at 800 rpm. The supernatant was then
centrifuged at 4 C for 20 min at 4,000 rpm. The final supernatant was
assessed for insulin and glucagon by radioimmunoassay (RIA). Results
were normalized to initial pancreas weight.
2.8. Pancreatic islet isolation, insulin secretion, and proliferation
assays
Islets from 10- to 12-week-old male mice were isolated by hand-
picking following pancreata digestion by Liberase [21]. After over-
night recovery in cell culture medium, insulin secretion measurements
were performed on batches of 10 islets. Islets were first pre-incubated
for 2 h in KrebseRinger Bicarbonate-HEPES buffer with bovine serum
albumin (KRBH-BSA) (120 mM of NaCl, 4 mM of KH2PO4, 20 mM of
HEPES, 1 mM of MgCl2, 1 mM of CaCl2, 5 mM of NaHCO3, and 0.5%
BSA, pH 7.4) supplemented with 2.8 mM of glucose. Medium was then
replaced with KRBH-BSA supplemented with either 2.8 mM or
16.7 mM of glucose, and incubations were continued for 1 h. Secreted
insulin and islet insulin contents were measured by radioimmuno-
assay. For islet insulin content measurements, islets were sonicated in
ethanol-acid. For proliferation measurements, 10 islets were placed on
extracellular matrix (ECM)-coated cell dishes (Novamed, Jerusalem,
Israel) and kept until monolayer formation (5e7 days). Proliferation
assessment was performed following Exendin-4 treatment (100 nM;
72 h). ECM plates were fixed with 4% paraformaldehyde (PFA),
washed with phosphate-buffered saline (PBS) (3), and permeabilized
with 0.3% Triton X-100 and 1% BSA (pH 7.4) for 30 min at room
temperature. Monolayers were then incubated in the presence of rabbithis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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anti-Ki67 antibody (diluted 1:500) for 1 h at room temperature.
Following washes with PBS (3), monolayers were incubated in the
dark with a goat anti-rabbit IgG antibody coupled to Alexa-Fluor 568
(diluted 1:400) for 1 h at room temperature. Finally, after three 3 with
PBS, cells were mounted on a coverslip with Vectashield-DAPI
(Reactolab SA, Servion, Switzerland) and observed with a Zeiss Axi-
ovision Fluorescence microscope. Quantification was made by
counting Ki67-positive cells using the ImageJ software (http://rsbweb.
nih.gov/ij/). Previous studies, using co-staining for Glut2, showed that
in these culture conditions 95% of proliferating cells were beta-cells
(b-cells) [22].
2.9. b-Cell purification
Pancreatic islets were incubated in RPMI 1640 supplemented with
10% fetal bovine serum (FBM), 1 mM of glutamine, and 1% pen/strep
with Exendin-4-Cy3 (100 nM) for 30 min at 37 C. Single-cell prep-
arations were then obtained by incubating islets for 1.5 min at 37 C,
with gentle pipetting, in Ca2þ and Mg2þ free PBS containing 0.24 mM
of ethylenediaminetetraacetic acid (EDTA) and 0.025% trypsin.
Digestion was stopped by adding RPMI 1640 supplemented with 10%
FBS, 1 mM of glutamine and 1% pen/strep. Dispersed islet cells were
resuspended in 300e500 ml of KRBH-1% BSA pH 7.4 supplemented
with 2.5 mM of glucose, 5 mM of EDTA and 1 mg/mL of 40,6-
diamidino-2-phenylindole (DAPI). b-cells were purified by
fluorescence-activated cell sorting using a 4-laser MoFlo ASTRIOS
EQ cell sorter (Beckman Coulter, Indianapolis, USA) using a 100-mm
nozzle. After gating out the doublets and dead cells (DAPI positive),
Cy3-positive cells detected using the 561 nm laser were selected.
2.10. Histomorphometric analysis and immunofluorescence
detection
Histomorphometric and b-cell proliferation analysis were performed
using 5-mm-thick sections from 4% paraformaldehyde (PFA)-fixed and
paraffin-embedded pancreata. b-cell mass was measured by histo-
morphometry [21,23]. Briefly, for each condition, 6 sections per
pancreas and 4e6 pancreata were analyzed, representing a total of
>500 islets. b-Cell surface area was measured using the ImageJ
software. b-cell mass was calculated by multiplying the b-cell area by
the pancreas weight. For b-cell proliferation and a-cell mass mea-
surements, pancreas sections were incubated overnight at 4 C with a
rabbit anti-Ki67 antibody (diluted 1:100) and guinea pig anti-glucagon
antibody (diluted 1:500) and washed 3 times with PBS. The sections
were then incubated for 1 h with Alexa-Fluor 568-labeled goat anti-
rabbit IgG antibody and Alexa-Fluor 488-labeled goat anti-guinea pig
IgG antibody, washed with PB,S and then mounted with Vectashield
containing DAPI. Ki67-positive cells were counted over islet areas
defined by glucagon staining in 50e100 islets. The analysis was
performed using the ImageJ software. Only non-glucagon, Ki67-
positive cells were counted. Because b-cells form the majority of
the islets non-alpha cells, we considered the Ki67-positive cells as
representing proliferating b-cells. Preceding experiments also showed
that the percent of Ki67/Glut2 double-positive cells was only marginally
different from the number of total Ki67-positive cells [22,24]. Glucagon
staining was used for a-cell mass measurements.
For immunofluorescence detection of islet Glut2, insulin, and glucagon,
mice were fixed by intracardiac perfusion with cold 4% PFA. Pancreata
were then excised, incubated in % PFA for 4 h and overnight in a 30%
sucrose solution before being frozen at 80 C in optimal cutting
temperature (OCT) compound. Twenty-micrometer cryosections were
prepared, blocked in PBS supplemented with 3% BSA and 0.3% Triton
X-10,0 and then incubated at 4 C overnight with rabbit anti-Glut2MOLECULAR METABOLISM 35 (2020) 100958  2020 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.com(diluted 1:500), guinea pig anti-insulin (diluted 1:500), and guinea
pig anti-glucagon (diluted 1:500). Primary antibodies were then
detected with an Alexa-Fluor 488-labeled goat anti-rabbit IgG antibody
or a goat anti-guinea pig IgG antibody (diluted 1:200).
2.11. RNA sequencing analysis
Integrity of islet RNA was verified on a fragment analyzer (Agilent
Technologies, Inc., Santa Clara, CA 95051, USA), and all preparations
had an RNA quality number (RQN) between 8.2 and 9.3. RNA-seq li-
braries were prepared using 250 ng of total RNA and the Illumina
TruSeq Stranded mRNA reagents (Illumina; San Diego, California,
USA). Cluster generation was performed with the resulting libraries
using the Illumina TruSeq SR Cluster Kit v4 reagents and sequenced on
the Illumina HiSeq 2500 using TruSeq SBS Kit v4 reagents. A
sequencing depth of 31e46 million reads using 125 bp single-end
reads was used.
Reads were mapped with STAR-2.5.3a software [25] to the M.
musculus-mm 15 reference genome. Read counts for each gene were
generated with HTSeq-0.9.1 software [26] using as reference the
annotation index GRCm38.83 from ENSEMBL. Counts were filtered,
excluding those genes with less than one count per million in two li-
braries, and normalized using trimmed mean normalization method
(TMM) with ‘edgeR’ [27]. Pathway enrichment analysis of the genes
differentially expressed between Ctrl and bKlf6KO mice was performed
using the Kyoto Encyclopedia of Genes and Genomes KEGG and gene
ontology (GO) databases and the R library “clusterProfiler”. P-values
were adjusted for multiple comparisons using the Benjamini Hochberg
procedure (Benjamini and Hochberg 1995). Terms with an adjusted p-
value 0.05 were considered as overrepresented.
2.12. Data representation and statistics
Results are expressed as mean  SEM with significant p-values
ranging from 0.05 to 0.001 (*P < 0.05; **P < 0.01; ***P < 0.001).
Statistical analyses performed on the presented data were done with
Prism 6.0 using Student’s t-test, and two-way analysis of variance
(ANOVA) followed by Tukey’s post-hoc multiple comparison test.
3. RESULTS
3.1. Klf6 as a potential regulator of b-cell adaptation to metabolic
stress
To identify novel genes potentially involved in the control of b-cell
mass and function in response to metabolic stress, we previously
performed a study where mice from six different strains were fed with
a regular chow (RC) or a HFHS diet for 2, 10, 30, and 90 days [14]. At
each time point, mice were tested for multiple metabolic phenotypes,
and their islets were isolated for RNASeq analysis. WGCNA led to the
identification of gene modules, i.e., groups of genes whose expression
is similarly regulated across all mouse groups. These modules were
then correlated with the measured phenotypes, and the results are
represented as a heat map (Supplementary Fig. 1a and Ref. [14]. Here,
we further investigated the Thistle 3 module, which showed strong
correlation with plasma insulin levels at 0, 15, and 90 min of an oral
glucose tolerance test. This module contains 114 genes, and the
transcription factor Klf6 (Krüppel-like Factor 6), is among the genes
that were most negatively correlated with insulinemia and strongly
associated with module membership (Supplementary Fig. 1b). To have
an indication of a potential association of KLF6 with diabetes in human
islets, we checked its level of expression in a large transcriptomic
database of islets from brain-dead, non-diabetic and type 2 diabetic
donors [28]. This data showed statistically significantly higherccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 3
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Figure 1: b-Cell-specific Inactivation of Klf6. (a) Structure of the modified Klf6 allele (top) and Klf6 allele after Ins1Cre-mediated recombination (middle and bottom). (b) PCR
analysis of Klf6 recombination using primers shown in a) in the indicated tissues of 12-week-old mice. PCR of genomic DNA from islets of bKlf6KO mice yields a 3,000-bp band
using Primers 1 and 2, and a 750-bp band using Primers 3 and 4. Primers 2 and 4 yield a 600-bp band. (c) qRT-PCR analysis of Klf6 expression in islets (n ¼ 11e12). Two-tailed
unpaired Student’s t-test. Error bars represent SEM.
Original Articleexpression of KLF6 mRNA in type 2 diabetic islets (log2fold-
change ¼ 0.27, adj. p-value 0.015) (Supplementary Fig. 1c).
3.2. Generation of b-cell-specific Klf6 conditional knockout mice
To investigate the role of Klf6 in b-cells, we generated mice with a b-
cell-specific inactivation of this gene by crossing Klf6flox/flox mice [20]
with Ins1Cre/þ mice [19] to generate Klf6flox/flox;Ins1Cre/þ (bKlf6KO)
mice and Klf6flox/flox;Ins1þ/þ (Ctrl) mice. Figure 1 shows that Cre-
mediated recombination resulted in the inversion of exons 2 and 3,
leading to inactivation of Klf6. Genotyping was performed with the
primers indicated in Figure 1A, and recombination was observed only
in islets (Figure 1B). Quantitative RT-PCR analysis showed a 40%
reduction of Klf6 expression in islets isolated from bKlf6KO mice
(Figure 1C). This indicated that Klf6 was also expressed in non-b-cells.
Quantitative RT-PCR analysis performed with RNA extracted from cell
sorter purified b- and non-b-cells shows a 3-fold higher expression of
Klf6 in non-b-cells (Supplementary Fig. 2), in agreement with pub-
lished data [29]. Thus, the remaining Klf6 expression in islets from
bKlf6KO mice is consistent with it being expressed at a 3-fold higher
level in non-b-cells, which represent 30% of islet cells. No gross
morphological difference could be observed between Ctrl and bKlf6KO
mice (Supplementary Fig. 3).
3.3. Normal glucose homeostasis, b-cell mass, and insulin
secretion in bKlf6KO mice
We first assessed glucose homeostasis as well as b-cell mass and
function in regular chow (RC)-fed bKlf6KO mice. These mice had
similar body weight, fasted, fed, and fasted/refed glycemia, as well as
plasma insulin and glucagon levels as their control littermates
(Supplementary Figs. 4aed). Their total pancreas and isolated islet
insulin content (Supplementary Figs. 4e and f) were similar to that of
Ctrl mice. GSIS assays using isolated islets from both types of mice
yielded identical results (Supplementary Figs. 4g) and i. p. glucose
tolerance tests performed on 12- and 36-week-old male and female4 MOLECULAR METABOLISM 35 (2020) 100958  2020 The Authors. Published by Elsevier GmbH. Tmice were also indistinguishable (Supplementary Figs. 4hek).
Pancreatic weights (not shown) and islet morphologies (Supplementary
Fig. 5) were indistinguishable between genotypes.
3.4. Reduced b-cell mass expansion in bKlf6KO mice in response
to pregnancy
Because inactivation of Klf6 did not impact b-cell mass and function in
non-challenged conditions, we tested whether metabolic stress would
reveal a role for Klf6. In a first set of experiments, we analyzed b-cell
proliferation and mass during gestation, an insulin-resistant condition
associated with compensatory b-cell growth [30]. Pancreatic weights
(not shown) and islet morphologies (Supplementary Fig. 5) were
indistinguishable between genotypes at 14 days of pregnancy. We
analyzed Ki67 staining in b-cells at day 14 and b-cell mass at day 18
of pregnancy. Ctrl and bKlf6KO mice displayed similar blood glucose
and plasma insulin levels throughout gestation (Figure 2A,B) but b-cell
proliferation increased by 6.5-fold in Ctrl mice as compared to 4-fold in
bKlf6KO (Figure 2C,D). As a result, b-cell mass increased by 2.3-fold
in Ctrl mice as compared to 1.7-fold in bKlf6KO mice (Figure 2E). The
difference in b-cell mass was related to a higher number of islets per
pancreas in Ctrl mice rather than to a change in islet size distribution
(Figure 2F,G).
3.5. Reduced b-cell mass expansion in bKlf6KO mice in response
to high-fat high-sucrose diet
In the second approach, we fed 6-week-old Ctrl and bKlf6KOmale and
female mice for an additional 22 weeks with a RC or an HFHS diet.
Feeding a high-energy diet induced a similar increase in body weight,
glucose intolerance, and in vivo GSIS in both types of mice
(Supplementary Fig. 6). Pancreatic weights (not shown) and islet
morphologies (Supplementary Fig. 5) were indistinguishable between
genotypes at the end of the HFHS feeding period. b-cell proliferation
was, however, markedly lower in male and female bKlf6KO mice as








Figure 2: Reduced b-cell Mass Expansion During Pregnancy in bKlf6KO Mice. (a) Blood glucose and (b) plasma insulin levels of 10e12-week-old female mice taken in non-
pregnant mice and mice at 14 and 18 days of pregnancy (n ¼ 4e6). (c) Quantification of Ki67-positive b-cells over islet cell surface in non-pregnant and 14-day pregnant mice
(n ¼ 5e8). (d) Representative immunofluorescence detection of Ki67 in Ctrl and bKlf6KO mice. Scale bar: 50 mm. (e) b-cell mass in response to pregnancy (day 18). (f) Islet
density and (g) size distribution following 18 days of gestation (n ¼ 5). Error bars represent SEM. Statistical analyses were performed using a two-way ANOVA (Bonferonni’s post-
hoc test) *P < 0.05; **P < 0.01; ***P < 0.001.
MOLECULAR METABOLISM 35 (2020) 100958  2020 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 3: Reduced b-cell Mass Expansion in HFHS-Fed bKlf6KO Mice. (a,e) Quantification of Ki67-positive b-cells over islet cell surface in Ctrl and bKlf6KO mice fed from 6
weeks of age for 22 weeks on regular chow diet (RC) or high-fat high-sucrose diet (HFHS) (n ¼ 4e6). (b,f) b-cell mass in RC or HFHS fed mice. (c,g) Islet density and (d,h) size
distribution following 22 weeks on respective diets (n ¼ 5). Error bars represent SEM. Statistical analyses were performed using a two-way ANOVA (Bonferonni’s post-hoc test)
*P < 0.05; **P < 0.01; ***P < 0.001.
Original Articlereduced b-cell mass expansion (Figure 3B,F). HFHS feeding led to shift
in the distribution in islet sizes to higher values (Figure 3D,H) and, in
female bKlf6KO mice, a reduction in islet numbers (Figure 3G).
3.6. Reduced b-cell mass expansion in bKlf6KO mice during S961
treatment
Insulin resistance induced by chronic delivery of the insulin receptor
antagonist S961 [31] leads to rapid development of hyperglycemia
and hyperinsulinemia. Here, we treated Ctrl and bKlf6KO male mice
for 2 and 7 days with saline or S961. This induced a strong hyper-
glycemia from the first day of treatment until the end of the experi-
ment in both groups of mice (Figure 4A). Insulinemia was similarly
elevated in Ctrl and bKlf6KO mice at day 1 of treatment but was
reduced by half in bKlf6KO mice at day 7 (Figure 4B), at which time
the total pancreatic insulin content was also reduced by 50% in the
pancreata of bKlf6KO mice (Figure 4C). The pancreatic glucagon
contents (Figure 4D), body weights (Figure 4E), and pancreas weights
(not shown) remained identical in S961-treated Ctrl and bKlf6KO
mice. However, unexpectedly, the b-cell section area was reduced by
40% by S961 treatment in both groups of mice (Supplementary
Fig. 7), indicating that S961 treatment also induced a reduction in
b-cell volume.
We next assessed b-cell proliferation and mass in male mice treated
for 7 days with saline or S961. Figure 5A shows that the proliferation
rate was increased by 5-fold in Ctrl mice and by 3-fold in bKlf6KO
mice. This led to a b-cell mass increase in S961-treated mice that
reached 2.5 mg/pancreas in Ctrl mice but only 2.0 mg/pancreas in
bKlf6KO mice (Figure 5B). This lower b-cell mass was due to a
decrease in the total number of islets, which displays the same size
distribution as in S961-treated Ctrl mice (Figure 5C,D).
Together, the above data showed impaired b-cell mass expansion in
bKlf6KO mice in response to insulin resistance of pregnancy, HFHS
diet feeding, or induced by pharmacological inhibition of the insulin6 MOLECULAR METABOLISM 35 (2020) 100958  2020 The Authors. Published by Elsevier GmbH. Treceptor. This indicates that Klf6 is necessary for the full compensatory
b-cell proliferation to insulin resistance.
3.7. Klf6 protects b-cells against dedifferentiation
To identify the changes in transcript expression resulting from Klf6
inactivation in b-cells, we performed RNASeq analysis of islets isolated
from Ctrl and bKlf6KO male mice treated for 2 days with saline or
S961. We selected this treatment time as we searched for early
transcriptional events leading to defective b-cell adaptation and tried to
minimize the changes in gene expression due to long-term metabolic
alterations. In this series of treated mice, the glycemia was already
markedly increased after 1 day of treatment and reached the usual
maximal value of 30 mM at day 2 (Supplementary Fig. 8a). Plasma
insulin levels were very high at day 1 of treatment in both Ctrl and
bKlf6KO mice but, at day 2, they were already reduced by 20% in
bKlf6KO mice as compared to Ctrl mice (Supplementary Fig. 8b).
Analysis of genes differentially expressed in islets from saline or S961-
treated Ctrl and bKlf6KO mice is presented as volcano plots
(Figure 6A). The complete lists of differentially expressed genes are
presented in Suppl. Tables 1 and 2. GO analysis of genes differentially
regulated in islets from saline-treated Ctrl and bKlf6KO mice
(Figure 6B, Supplementary Tables 3a and b), revealed that most
pathways over-represented in knockout islets were associated with
cell cycle regulation (“mitotic cell division”, “regulation of cell cycle
process”, etc.) and a few with hexose metabolic processes. The
absence of Klf6 did not lead to impaired proliferation under unchal-
lenged conditions in vivo, yet islets from bKlf6KO mice had lower Ki67
staining than Ctrl islets when cultured as monolayers on an extracel-
lular matrix in the presence or absence of Exendin-4 (Supplementary
Fig. 9). In the hexose metabolic GO term, 3 glycolytic genes control-
ling the same step were present, Pfkfb2 (6-phosphofructo-2-kinase/
Fructose-2,6-Biphosphatase 2), reduced by 34% in bKlf6KO compared




Figure 4: Impaired Insulinemic Response to Insulin Resistance in bKlf6KO Mice. Twelve-week-old male Ctrl and bKlf6KO mice were treated with saline or the insulin
receptor antagonist S961 for 7 days. (a) Glycemia (n ¼ 7e10) (b) insulinemia at days 1 (n ¼ 9e15) and 7 (n ¼ 9e14). (c) Pancreatic insulin and (d) glucagon contents at day 7 of
treatment (n ¼ 9e11) (e) body weight (n ¼ 4e10). Statistical analyses have been performed by two-way ANOVA (Bonferonni’s post-hoc test). ***P < 0.001. Statistical analyses
in c and d were done using a two-tailed unpaired Student’s t-test. Error bars represent SEM.allosteric glycolysis activator fructose 2,6-bisphosphate (Fru-2,6-P2),
Fbp2 (fructose bisphosphatase 2), increased by 2.4 fold, which cata-
lyzes the hydrolysis of Frc-1,6-P2 into Frc-6-P, and Tigar (P53 Induced
Glycolysis Regulatory Phosphatase), reduced by 30%, an enzyme that
hydrolyzes both Frc-1,6-P2 and Frc-2,6-P2 into Frc-6-P thus increasing
the reverse glycolytic pathway potentially leading to increased pro-
duction of NADPH through the pentose phosphate shunt [32e34].
GO analysis of genes differentially expressed in islets from Ctrl and
bKlf6KO mice under S961 treatment (Figure 6C, Supplementary
Tables 4a and b) revealed enrichment in cell division genes (“mitotic
nuclear division”, “regulation of cell cycle process”) and a strikingA B C
Figure 5: Reduced b-cell Mass Expansion in S961-Treated bKlf6KO Mice. (a) Quantifi
for 7 days (n ¼ 5e7). (b) b-cell mass in response to saline and S961 treatment. (c) Islet d
Statistical analyses were performed using a two-way ANOVA (Bonferonni’s post-hoc test)
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www.molecularmetabolism.comincrease in terms related to glucose metabolism and insulin secretion
(“hormone transport”, “hormone secretion”, “exocytosis”, “glucose
metabolic process”, and others) (Figure 6C).
A more detailed analysis of the genes that were dysregulated in islets
from bKlf6KO as compared to Ctrl mice following S961 treatment
revealed: (Figure 7A) i) a 30% reduced expression of genes controlling
different steps in GSIS, including Slc2a2, Slc30a8, Igf1r, Ffar1,
Vdca1d, Atp2a2, Vamp2, and Sytl4; ii) a reduced expression of Pdx1,
Nkx6.1, Foxa2, and Foxo1, essential mature b-cell transcription factors
[7,35e37]; iii) an increased expression of several mRNAs encoding
dedifferentiation markers, including Gast, Aldh1a3, Serpina7, Vim, andD
cation of Ki67-positive b-cells over islet cell surface in mice treated with saline or S961
ensity and (d) size distribution of islets following S961 treatment for 7 days (n ¼ 4e5).
*P < 0.05; **P < 0.01; ***P < 0.001. Error bars represent SEM.
ccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 7
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Figure 6: Transcriptomic Analyses of Islets from Mice Treated with Saline and S961. Ctrl and bKlf6KO mice were treated with saline or S961 for 2 days before islet
harvesting. (a) Volcano plots showing the number of islet genes differentially expressed between genotypes (Ctrl and bKlf6KO) following treatment. Selected gene ontology analysis
of differentially expressed genes following (b) saline and (c) S961. *genes associated with metabolic processes.
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Figure 7: Loss of Klf6 in the b-cell Increases Dedifferentiated Phenotype Upon S961 Treatment. (a) Differential gene expression based on RNA-sequencing performed on
islets (n ¼ 8) harvested from Ctrl and bKlf6KO mice treated with S961 for 2 days. Data are represented as fold change of mRNA of specific genes. (b) RT-PCR of islets harvested
from mice treated with S961 for a 7-day period (n ¼ 5). Two-tailed unpaired Student’s t-test. Error bars represent SEM. (c) Immunofluorescence of insulin, (d) Glut2 and (e)
chromogranin A in Ctrl and bKlf6KO pancreata following saline or S961 treatment for 7 days (n ¼ 4). Scale bar: 50 mm.Slc18a2 as well as iv) expression of the “disallowed genes”, Ldha,
Hk1, Slc16a2, Oat, Igfbp4, Mylk, Ly6a, Pcolce, Parp3, and Ndrg2
[1,7,36e43].
After 7 days of treatment with S961, the expression of Ins1, Ins2,
Slc2a2, and Slc30a8, as determined by RT-QPCR analysis, was still
more reduced in islets from bKlf6KO than in Ctrl mice (Figure 7B).
Immunofluorescence microscopy detection of insulin and Glut2
confirmed lower expression of both proteins in islets of S961-treated
bKlf6KO as compared to Ctrl mice (Figure 7C,D). The endocrine
markers Foxo1 and Aldh1a3 were, however, no longer differentially
expressed between Ctrl and bKlf6KO islets (Figure 7B). Immuno-
staining for Aldh1a3, a protein induced in a subset of dedifferentiated
b-cells, was similarly increased in islets from both types of mice after
S961 treatment (Supplementary Fig. 10). Finally, chromogranin AMOLECULAR METABOLISM 35 (2020) 100958  2020 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.comshowed homogenous expression over the whole islets, although the
staining intensity was lower after S961 than after saline treatment
(Figure 7E). There was no difference in chromogranin A mRNA
expression between islets from Ctrl and bKlf6KO mice treated with
saline or S961 as indicated by the RNASeq data (not shown).
As previous reports indicated that hyperglycemia induces trans-
differentiation of b-cells into a-cells [7,44], we measured a-cell mass
in the pancreas of Ctrl and bKlf6KO mice after 7 days of saline or S961
treatment. Figure 8A, B shows that the a-cell mass was not increased
by S961 treatment in Ctrl mice but was increased by 60% in islets from
S961-treated bKlf6KO mice, and this corresponded to a 60% percent
increase in islet glucagon mRNA (Figure 8C). Ki67 staining also
revealed a higher proliferation rate of a-cells in S961-treated bKlf6KO
mice than in Ctrl mice (Figure 8D).ccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 9
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D E F
Figure 8: Increased a-cells Mass and b-cell Transdifferentiation in S961-Treated bKlf6KO Mice. Ctrl and bKlf6KO mice were administered S961 or saline for 7 days. (a)
Immunofluorescence of glucagon-producing cells. Scale bar: 50 mm. (b) Measurement of a-cell mass (n ¼ 3e5). (c) Islet gcg mRNA expression (n ¼ 9e13). (d) Quantification of
Ki67-positive a-cell over islet cell surface (n ¼ 3e5). (e) Lineage tracing experiments were performed using Ctrl and bKlf6KO expressing tdtomato from the Rosa26 locus.
Quantification of glucagon-positive cells expressing tdtomato in Ctrl and bKlf6KO following S961 treatment for 7 days with an example of immunostaining (n ¼ 4e7). Statistical
analyses were performed using two-way ANOVA (Bonferonni’s post-hoc) *P < 0.05; **P < 0.01; ***P < 0.001. Statistical analysis in c was done using two-tailed unpaired
Student’s t-test. Error bars represent SEM.
Original ArticleTo determine whether the increased number of a-cells can be
accounted for by transdifferentiation of b-cells, we generated
ins1Cre;Rosa26tdtomato and bKlf6KO; Rosa26tdtomato mice and
treated them for 7 days with S961. We then quantified the number of
glucagon positive cells also expressing tdtomato. Approximately 4%
of a-cells in ins1Cre;Rosa26tdtomato mice were also positive for
tdtomato and 8% in bKlf6KO; Rosa26tdtomato mice (Figure 8E).
Thus, S961 treatment induced a larger number of b-cells to
transdifferentiate into glucagon-producing cells in bKlf6KO mice
than in Ctrl mice, suggesting that the increase in a-cell mass may
result from both b-cell transdifferentiation and increased prolifera-
tion of a-cells.
4. DISCUSSION
Here, we show that Klf6 is required for the full proliferation response of
b-cells to the insulin resistance of pregnancy, HFHS diet, and induced
by insulin receptor antagonism. When insulin resistance is associated
with marked hyperglycemia, as in S961-treated mice, Klf6 also pro-
tects b-cells against dedifferentiation and reduces their trans-
differentiation into a-cells. Klf6 is, thus, a transcription factor that is
required for preserving mature b-cell functional adaptation to insulin
resistance.
Klf6 is a member of the Krüppel-like family of transcription factors that
contains 18 isoforms [45]. These have various functions in cell cycle
progression, apoptosis, and cancer development [46e49], and Klf6 is
also associated with non-alcoholic fatty liver disease [50,51] and
diabetic nephropathy [52,53]. Here, we identified Klf6 through a10 MOLECULAR METABOLISM 35 (2020) 100958  2020 The Authors. Published by Elsevier GmbH. Tsystems biology approach aimed at identifying novel regulators of b-
cell adaptation to metabolic stress [14]. We found that Klf6 expression
is not required for the normal development of adult b-cell mass and
function nor for their functional stability over time when mice are fed
RC. Only when an additional stress is imposed, such as during
gestation when insulin resistance develops but mice remain normo-
glycemic, does the absence of Klf6 lead to impaired b-cell proliferation
and mass expansion. In HFHS-fed mice, glucose intolerance and
in vivo glucose-stimulated insulin secretion evolved similarly in
bKlf6KO and Ctrl mice, but b-cell proliferation and mass were
significantly less induced in bKlf6KO mouse islets. Here, we fed the
mice with an HFHS diet for 22 weeks a period of time that may not be
sufficient for the b-cell mass expansion defect observed to cause more
severe glucose intolerance in bKlf6KO mice than in Ctrl mice. When
bKlf6KO mice were treated with S961, a condition that induces rapid
and massive hyperglycemia [31,54], reduced b-cell proliferation, and
lower mass expansion was associated with a rapid decline in plasma
insulin as compared to S961-treated Ctrl mice. Thus, combining in-
sulin resistance with severe hyperglycemia induces stronger b-cell
dysfunctions in bKlf6KO mice highlighting the important protective role
of Klf6 in these conditions.
To obtain insights into the gene network controlling defective b-cell
adaptation in bKlf6KOmice, we performed islet transcriptomic analysis
and searched for genes differentially expressed between Ctrl and
bKlf6KO mouse islets in saline or S961 treated mice. In saline treated
mice, comparative transcriptomic analysis showed that the differen-
tially expressed genes were enriched in genes controlling the cell
cycle. Most of these genes were upregulated in bKlf6KO islet cellshis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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even though these cells have lower proliferation capacity than those in
Ctrl islets as tested in islets cultured as monolayers. Nevertheless,
Cdkn3, a cell cycle inhibitor [55], was overexpressed 6-fold in bKlf6KO
islets and this may explain the reduced b-cell proliferation capacity. On
the other hand, 3 glycolytic genes were also dysregulated, Pfkfb2,
Fbp2, and Tigar. These genes control the production and hydrolysis of
fructose-1,6-bisphosphate, a key regulatory step in glycolysis and
neoglucogenesis. Activating the neoglucogenic direction of this
pathway also leads to increased activity of the pentose phosphate
pathway, a supplier of Nicotinamide adenine dinucleotide phosphate
(NADPH) required for protection against oxidative stress and for the
biosynthesis of new molecules necessary for cell proliferation [32e
34]. Thus, in regular feeding conditions and when normoglycemia is
preserved, Klf6 mainly controls the expression of proliferation genes
and of a small group of glycolytic genes possibly required for sup-
porting proliferation through redirecting glucose carbons to biosyn-
thetic activities. In the present study, we have not analyzed whether
any of these genes are direct or indirect transcriptional targets of Klf6.
However, a study performed in primary mouse oligodendrocyte pro-
genitors and immature oligodendrocytes identified genes that were
direct targets of Klf6-binding [56]. Among those, the following were
also found to be dysregulated in islets from bKlf6KO mice treated with
S961: Ly6a, Oat, and Slc16a2 (disallowed genes), Serpina7 and Vim
(dedifferentiation markers), and Slc30a8, gene linked to insulin
secretion.
bKlf6KO mice and Ctrl mice under S961 treatment display severe
insulin resistance and hyperglycemia. These lead to more important
differences in their islets transcriptional program with several groups
of genes associated with b-cell dedifferentiation in addition to the “cell
cycle” and “glucose metabolism” genes as described in diabetic mice
[7,57] and hyperglycemic rats [6]. These changes include down-
expression of genes controlling GSIS, reduced expression of b-cell-
specific transcription factors, and the overexpression of disallowed
genes that negatively interfere with GSIS. These observations therefore
suggest that Klf6 is a critical guardian of b-cell mass and identity when
insulin resistance and hyperglycemia develop. In this context, our
observation that KLF6 expression is increased in islets from type 2
diabetic organ donors suggests that, in humans, its induction aims at
protecting b-cells against dedifferentiation. Another aspect of
hyperglycemia-induced dedifferentiation is the capacity of b-cells to
transdifferentiate into a-cells [7,44]. We show that S961 treatment
induces an approximately two-fold higher rate of b-cell trans-
differentiation into a-cells when Klf6 is absent.
Thus, our data demonstrates that Klf6 is required for the normal
proliferative response of b-cells induced by insulin resistance to
protect b-cells against dedifferentiation induced by severe insulin
resistance and hyperglycemia and to limit b-cell transdifferentiation
into a-cells. It is interesting to compare the role of Klf6 with that of
Foxo1. In their landmark paper, Talchai et al. [7] report that b-cell
specific Foxo1/ mice display reduced b-cell mass, increased a-cell
mass, impaired fasting glucose with hypoinsulinemia and hyper-
glucagonemia only when metabolically challenged by multiple preg-
nancies or aging. Inactivation of Foxo1 is associated with
compensatory increased expression of Foxo3 and Foxo4 and mice
with triple Foxo knockout developed glucose intolerance due to
reduced insulin secretion when fed with RC [7,57]. Thus, in analogy
with the Foxo transcription factor studies, inactivation of Klf6 does not
induce any islet phenotype under RC, but genetic inactivation of
additional Klf family members may generate a stronger diabetic
phenotype. Indeed, Klf10 [58] and Klf11 [59] have been reported as
potential additional regulators of b-cell function. It is also interestingMOLECULAR METABOLISM 35 (2020) 100958  2020 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.comto note that Klf6 expression in purified mouse b-cells has been found
to decrease with age [60], potentially explaining the reduced prolif-
eration capacity of old b-cells [61].
5. CONCLUSION
In conclusion, our present study identifies Klf6 as a transcription factor
that controls b-cell proliferation induced by the insulin resistance of
pregnancy, the consumption of high-energy-containing food, and
induced by pharmacological induction of insulin resistance. In the latter
condition, which is also associated with strong hyperglycemia, Klf6
also restricts b-cell dedifferentiation and transdifferentiation into
glucagon-producing a-cells. Thus, Klf6 expression has a protective
effect against type 2 diabetes development, and its overexpression
may protect against appearance of this disease.
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